Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor

US8440694B2 · kind B2 · utility

Assignee

• Abbott GmbH & Co. KG · DE

Inventors

• Sean Colm Turner · Ludwigshafen, DE
• Wilfried Braje · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Udo Lange · Ludwigshafen, DE
• Karla Drescher · Ludwigshafen, DE
• Karsten Wicke · Ludwigshafen, DE
• Liliane Unger · Ludwigshafen, DE
• Mario Mezler · Ludwigshafen, DE
• Matthias Mayrer · Biblis, DE
• Wolfgang Wernet · Ludwigshafen, DE

Key dates

• Filing date: Sep 13, 2012
• Grant date: May 14, 2013
• Expiry date: Sep 13, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X′, Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1.